Exenatide as a Novel Weight Loss Modality in Patients Without Diabetes

Moreno, Jessica L.; Willett, Kristine C.; Desilets, Alicia R

doi:10.1345/aph.1r372

Cited by 11 publications

(18 citation statements)

References 23 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These data are consistent with the concept that an effect of exenatide on gastric emptying may contribute to the weight loss observed in larger, longer duration, randomized, placebo‐controlled trials (Moreno et al. ). These results are also consistent with effects of exenatide on gastric emptying which are temporally associated with reduced postprandial glycemia in patients with type 2 diabetes mellitus (Linnebjerg et al.…”

Section: Discussionsupporting

confidence: 89%

See 1 more Smart Citation

Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study

et al. 2015

View full text Add to dashboard Cite

Obesity is associated with differences in satiety, gastric emptying (GE), gastric volume, and psychological traits. Exenatide, a short-acting glucagon-like peptide 1 (GLP-1) receptor agonist, is associated with variable weight loss. We compared the effects of exenatide, 5 μg, and placebo SQ, twice daily for 30 days on GE of solids and liquids (scintigraphy), satiety (ad libitum buffet meal), satiation (nutrient drink test, maximum tolerated volume [MTV]), and weight loss in 20 participants with documented accelerated GE of solids (T1/2 < 90 min). Exenatide delayed GE of solids (T1/2 [Δ] 86 min relative to placebo, P < 0.001) and reduced calorie intake at buffet meal ([Δ] 129 kcal compared to placebo). Median weight loss was −0.95 kg (IQR −0.7 to −2.1) for exenatide and −0.55 kg (0.3 to −2.1) for placebo (P = 0.23); 80% of exenatide group had documented reduction in weight. In the exenatide treatment group, there was an inverse correlation between gastric emptying T1/2 and MTV (R = −0.548, P = 0.089). The univariate association of weight change with posttreatment MTV was borderline (Rs = 0.43, P = 0.06); in the multiple regression model, posttreatment MTV was associated with weight change (P = 0.047). The effect of the short-acting GLP-1 receptor agonist, exenatide, on GE is associated with the change in food intake, and the latter impacts weight loss in response to exenatide treatment.

show abstract

Section: Discussionsupporting

confidence: 89%

“…; Moreno et al. ). Clearly, findings of this pilot study need replication in a larger, longer duration, randomized clinical trial in patients with accelerated gastric emptying.…”

Section: Discussionmentioning

confidence: 97%

Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study

et al. 2015

View full text Add to dashboard Cite

show abstract

“…However, stimulation of short-term, episodic signals represents a promising therapeutic option, as small clinical studies with exendin-4 have shown a potential for sustained weight loss in obese individuals [262], and even more promising may be multi-hormone "cocktail" treatments, which target both episodic and tonic signals to bring about weight loss [263]. Similarly, newly developed PEGylated peptide analogues, such as (pGlu-Gln)-CCK-8 with increased enzymatic stability that impede rapid degradation are also promising therapeutic options for obesity [264].…”

Section: Discussionmentioning

confidence: 99%

The modulatory role of high fat feeding on gastrointestinal signals in obesity

Duca

Sakar

Covașă

2013

The Journal of Nutritional Biochemistry

View full text Add to dashboard Cite

“…Both liraglutide and exenatide twice/day have been evaluated for weight loss in patients without diabetes. A systematic literature review published in 2012 identified five studies examining the effects of exenatide on weight in patients without diabetes . Patients enrolled in these studies were overweight or obese, with a family history or other indications of prediabetes.…”

Section: Emerging Usesmentioning

confidence: 99%

“…A systematic literature review published in 2012 identified five studies examining the effects of exenatide on weight in patients without diabetes. 23 Patients enrolled in these studies were overweight or obese, with a family history or other indications of prediabetes. In this population, weight loss ranged from 2.0 to 5.1 kg.…”

Section: Glp-1 Ra Use In Obesity and Weight Managementmentioning

confidence: 99%

GLP-1 Receptor Agonists for Type 2 Diabetes Mellitus: Recent Developments and Emerging Agents

Trujillo

Nuffer

2014

Pharmacotherapy

View full text Add to dashboard Cite

More than 26 million people in the United States have type 2 diabetes mellitus (T2D). Many treatment options exist, but achieving long-term glycemic control in patients with T2D remains challenging. The glucagon-like peptide-1 receptor agonists (GLP-1 RAs) offer a treatment option that improves glycemic control and reduces weight, with a low risk of hypoglycemia. They have emerged as attractive options for the treatment of T2D, and significant advances and developments continue to be published regarding these agents. To identify relevant literature on emerging issues related to GLP-1 RAs, a search of the MEDLINE database was performed. Studies published in English evaluating the safety and efficacy of GLP-1 RAs were analyzed. Because of their advantages and unique mechanism of action, GLP-1 RAs are currently being studied in new clinical areas, including in combination with basal insulin, as adjunctive therapy in type 1 diabetes, and for weight loss. In addition, there are several emerging agents in development. Lixisenatide is a once-daily GLP-1 RA that targets postprandial glucose and may be most useful when added to basal insulin as an alternative to rapid-acting insulin. Albiglutide and dulaglutide are once-weekly GLP-1 RAs that may offer more convenient dosing. The most common adverse effects of all GLP-1 RA agents are gastrointestinal (e.g., nausea, diarrhea, and vomiting), but the rates of occurrence vary among agents. Due to the differences in pharmacokinetics, efficacy, rates of adverse effects, and administration requirements within the GLP-1 RA class, each agent should be evaluated independently. The future of GLP-1 RAs offers broader treatment options for T2D as well as potential in other treatment areas.

show abstract

Exenatide as a Novel Weight Loss Modality in Patients Without Diabetes

Cited by 11 publications

References 23 publications

Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study

Exenatide in obesity with accelerated gastric emptying: a randomized, pharmacodynamics study

The modulatory role of high fat feeding on gastrointestinal signals in obesity

GLP-1 Receptor Agonists for Type 2 Diabetes Mellitus: Recent Developments and Emerging Agents

Contact Info

Product

Resources

About